ANTITHROMBOTIC THERAPY TODAY. The report 1

By the WHO data, cardiovascular diseases are the most common causes of death all over the world, thus more four of five death cases from cardiovascular diseases occur as a result of an infarct and a stroke and has premature character. One of the reasons of development of these diseases is the thrombosis, i.e. formation of potentially lethal thrombs in vessels. Therefore working out and application antithrombotic agents is priority in medicine. This short review is dedicated to these drugs.

1. Koroleva A.A. Antitrombocitarnye preparaty dlya preduprezhdeniya i leche-niya aterotromboza: uchebnometodicheskoe posobie // Koroleva A.A., Zhuravkov Yu.L. – Mn.: Infoforum, 2012. – 38 s.

2. F. Franchi, F. Rollini, D.J. Angiolillo. Antithrombotic therapy for patiients with STEMI undergoing primary PCI. Nat. Rev. Cardiol.14(6), 2017, 361-379.

3. Konorev M.R. Kurs lekcij po klinicheskoj farmakologii: posobie // M.R. Konorev, O.V. Kurlyuk, T.M. Sobolenko i dr. (pod red.M.R. Konoreva). – Vitebsk: VGMU, 2020. – 382 s.

4. Ostryj infarkt miokarda s pod»emom ST elektrokardiogrammy: rossijskie klinicheskie rekomendacii // Moskva, 2020. – 158 s.

5. Rekomendacii ESC po vedeniyu pacientov s ostrym koronarnym sindromom bez stojkogo pod»ema segmenta ST 2020 // www.escardio.org/guidelines.

6. Capodanno D., Ferreiro J. L., Angiolillo D. J. Antiplatelet therapy: new pharmacolog-ical agents and changing paradigms //journal of Thrombosis and Haemostasis. – 2013, v. 11, p. 316–329.

7. Dominick J. Angiolillo, MD, PhD; Mattia Galli, MD; Jean-Philippe Collet, MD, PhD; Adnan Kastrati, MD; Michelle L. O‘Donoghue, MD, MPH. Antiplatelet therapy after percu-taneous coronary intervention. EuroIntervention 2022;17:e1371-e1396.

8. Patrono C., Coller B., Dallen J.E., et al. Platelet Factive drugs: the relationships among dose, effectiveness, and side effects// Chest 2001; 119:39-63.

9. Sychev D.A., Zyatenkov A.V., Kukes V.G. Klinicheskaya farmakogenetika antia-gregantov: vzglyad klinicheskogo farmakologa. Rossijskij kardiologicheskij zhurnal. 2007;(4):91-99.

10. Fizgerald D.J., Maree A. Aspirin and clopidogrel resistance. Hematology. 2007: 114-120.

11. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural out-comes in percutaneous coronary interventions: a pooled analysis of patient-level data. The Lancet. 2013.

12. Sami Abuqayyas, Shine Raju, John R. Bartholomew, Roulan Abu Hweij, Atul C. Mehta. Management of antithrombotic agents in patients undergoing flexible bronchoscopy. European Respiratory Review 2017 26: 170001.